NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma.
about
From mice to humans: developments in cancer immunoeditingCancer Immunoprevention and Public Health.New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escapeHLA-DR expression on myeloid cells is a potential prognostic factor in patients with high-risk neuroblastoma.Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
P2860
NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
NY-ESO-1-specific immunologica ...... ient with metastatic melanoma.
@en
NY-ESO-1-specific immunologica ...... ient with metastatic melanoma.
@nl
type
label
NY-ESO-1-specific immunologica ...... ient with metastatic melanoma.
@en
NY-ESO-1-specific immunologica ...... ient with metastatic melanoma.
@nl
prefLabel
NY-ESO-1-specific immunologica ...... ient with metastatic melanoma.
@en
NY-ESO-1-specific immunologica ...... ient with metastatic melanoma.
@nl
P2093
P2860
P1433
P1476
NY-ESO-1-specific immunologica ...... ient with metastatic melanoma.
@en
P2093
Alexander Knuth
Alexandro Landshammer
Carolin Schäfer
Elke Jäger
Gerd Ritter
Holger Moch
Lotta von Boehmer
Maries van den Broek
Muriel Mattle
P2860
P577
2013-07-15T00:00:00Z